PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Thiago VidottoFabiano P SaggioroTamara JamaspishviliDeise L ChescaClarissa G Picanço de AlbuquerqueRodolfo B ReisCharles H GrahamDavid M BermanD Robert SiemensJeremy A SquireMadhuri KotiPublished in: The Prostate (2019)
Our findings imply that PTEN deficiency is linked to an immunosuppressive state in PCa with distinct changes in the frequency of immune cell types in tumors from different metastatic sites. Our data suggest that determining PTEN status may also help guide the selection of patients for future immunotherapy trials in localized and metastatic PCa.
Keyphrases
- prostate cancer
- pi k akt
- cell proliferation
- small cell lung cancer
- squamous cell carcinoma
- end stage renal disease
- cell cycle arrest
- newly diagnosed
- induced apoptosis
- ejection fraction
- poor prognosis
- radical prostatectomy
- regulatory t cells
- peritoneal dialysis
- prognostic factors
- electronic health record
- signaling pathway
- current status
- big data
- patient reported outcomes
- oxidative stress
- machine learning
- binding protein
- cell death
- deep learning
- artificial intelligence
- data analysis
- patient reported
- smoking cessation
- long non coding rna